Some corticosteroids have been shown to be teratogenic after dermal application to laboratory animals.Ĭlobetasol propionate has not been tested for teratogenicity when applied topically however, it is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and mouse.
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels.
Teratogenic Effects: Pregnancy Category C. Gel should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae. If a favorable response does not occur promptly, use of TEMOVATE ® Gel should be discontinued until the infection has been adequately controlled.
#CLOBETASOL TOPICAL SKIN#
If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used.
#CLOBETASOL TOPICAL PATCH#
Such an observation should be corroborated with appropriate diagnostic patch testing. Allergic contact dermatitis with corticos-teroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. If irritation develops, TEMOVATE ® Gel should be discontinued and appropriate therapy instituted. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (see PRECAUTIONS: Pediatric Use). For information on systemic supplementation, see prescribing information for those products. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur that require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Patients receiving super-potent corticosteroids should not be treated for more than 2 weeks at a time, and only small areas should be treated at any one time due to the increased risk of HPA suppression.
#CLOBETASOL TOPICAL FREE#
plasma cortisol, and urinary free cortisol tests. This may be done by using the ACTH stimulation, A.M. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. Manifestations of Cushing syndrome, hyperglycemia, and glu-cosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on therapy. Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal from treatment. General: Clobetasol propionate is a highly potent topical corticosteroid that has been shown to suppress the HPA axis at doses as low as 2 g/day.
0 kommentar(er)
